Clinical Pharmacokinetics of Methotrexate1
- 1 January 1978
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 3 (1), 1-13
- https://doi.org/10.2165/00003088-197803010-00001
Abstract
No abstract availableThis publication has 59 references indexed in Scilit:
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977
- PURITY OF METHOTREXATEThe Lancet, 1975
- Reappearance of dihydrofolate reductase in rodent tissues following methotrexate administrationJournal of Pharmacokinetics and Biopharmaceutics, 1975
- Stoichiometric inhibition of mammalian dihydrofolate reductase by the γ-glutamyl metabolite of methotrexate, 4-amino-4-deoxy-N10-methylpteroylglutamyl-γ-glutamateBiochemical and Biophysical Research Communications, 1975
- Threshold Methotrexate Concentration for In Vivo Inhibition of DNA Synthesis in Normal and Tumorous Target TissuesJCI Insight, 1973
- Polygammaglutamyl metabolites of methotrexateBiochemical and Biophysical Research Communications, 1973
- METHOTREXATE IMPURITIESThe Lancet, 1972
- Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion patternEuropean Journal of Cancer (1965), 1972
- Methotrexate Hepatotoxicity in Psoriasis--Comparison of Different Dose RegimensBMJ, 1972
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948